Clinical trial
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
NCT00006226 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006226 |
|---|---|
| Title | Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia |
| Official title | A Phase II Trial of Thalidomide in Patients With Relapsed Chronic Lymphocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia |
| Intervention type | Drug, Other |
| Interventions | thalidomide, laboratory biomarker analysis |
| Enrollment | 41 |
| Start date | Sep 1, 2000 |
| Primary completion | Dec 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: